news

Single Use Bioprocess System Market Key Players, Size, Share, Analysis and Forecast To 2031

Single Use Bioprocess System Market 2022

Growing demand for single-use bioprocess systems due to their advantages of lesser cross-contamination chances provides a strong foothold for their use in the biopharmaceutical industry. Pharmaceutical and biotechnology companies are looking forward to continuous manufacturing of pharma products with optimizing speed and sterility assurance, which is expected to surge demand for single-use bioprocess systems. Use of disposable products for bioprocessing application enhances upstream and downstream processes with better safety, sterility, and reliability. Besides, continuous focus by key players to manufacture high quality and technologically-advanced disposable bioprocess systems is also expected to accelerate market growth.

Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/12142

Increasing investments toward manufacturing plant expansion and rising emphasis on low-cost disposable bioprocess product development by key market players are other major factors expected to aid market growth. The global single-use bioprocess systems market was valued at US$ 4.4 Bn in 2020, and is expected to exhibit a CAGR of close to 20% over the forecast period (2020 – 2030).

Company Profiles:

  • Thermo Fisher Scientific Inc.
  • Sartorius Stedim Biotech
  • Danaher Corporation
  • Merck Millipore
  • Eppendorf AG
  • Celltainer Biotech B.V.
  • Applikon Biotechnology
  • Cellexus Ltd.
  • Parker Hannifin Corp
  • Mettler-Toledo International, Inc.

Get To Know Methodology of Report@ https://www.persistencemarketresearch.com/methodology/12142

single-use-bioprocess-systems-market.jpg

Key Takeaways from Single-use Bioprocess Systems Market Study

  • The bioreactor segment by component held maximum value, owing to growing use of single-use bioreactors for cell culture and fermentation processes.
  • By application, GMP and commercial production captured a notable revenue share of more than 71%.
  • Increasing adoption of single-use bioprocess systems in biopharmaceutical companies is expected to result in remarkable revenue share of this segment.
  • North America is a most lucrative market with a revenue of around 34% in 2020; however, it will lose some of its market share over the next ten years.
  • Growing healthcare expenditure and increasing demand for low-cost biologics in Asian countries are expected to propel market growth in the region to more than one-third of the global share by 2030.
  • The markets in Russia, China, and Spain are anticipated to expand at CAGRs of 16%, 18.4%, and 17%, respectively, through 2030.

“Growing demand for disposable bioprocess systems to improve the manufacturing speed and efficacy of biologics at low cost is expected to flourish market growth and provide a competitive advantage to players,” says a Persistence Market Research analyst.

Access Full Report@ 

Do you already have an account? Log in here

Posted in: Asia USA/Canada

Join the discussion

0 comments

To read and post comments you need to login or register